Literature DB >> 3142353

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.

M Kresken1, B Wiedemann.   

Abstract

Since 1975, the group Resistenz of the Paul-Ehrlich-Gesellschaft für Chemotherapie has monitored the development of resistance in isolates of members of the family Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis in the Federal Republic of Germany, West Berlin, Austria, and Switzerland. Despite a marked increase in the use of 4-quinolones, there was no increase in the percentages of nalidixic acid-resistant strains of Enterobacteriaceae between 1975 and 1986. However, different bacterial species showed considerable variation, and there were also considerable differences in the percentages of nalidixic acid-resistant strains of Enterobacteriaceae from different centers. The frequency of resistance to fluoroquinolones was unchanged from 1983 to 1986 and was less than 4% in all species except P. aeruginosa. In this species, there was an increase from about 3 to 10% from 1983 to 1986 for strains for which the MIC was fourfold above the mode MIC of ciprofloxacin, enoxacin, and ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142353      PMCID: PMC172396          DOI: 10.1128/AAC.32.8.1285

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria.

Authors:  L G Burman
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

2.  In vitro emergence of Escherichia coli and Pseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid.

Authors:  J C Piffaretti; A Demarta; L Leidi-Bulla; R Peduzzi
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

3.  A critical evaluation of nalidixic acid in urinary-tract infections.

Authors:  A R Ronald; M Turck; R G Petersdorf
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

4.  The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo.

Authors:  P B Fernandes; C W Hanson; J M Stamm; C Vojtko; N L Shipkowitz; E St Martin
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

5.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

6.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

8.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.

Authors:  J H Tenney; R W Maack; G R Chippendale
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

View more
  35 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Changes in the sensitivity of urinary pathogens to quinolones between 1987 and 1990 in France.

Authors:  G Aubert; P P Levy; A Ros; R Meley; B Meley; A Bourge; G Dorche
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

Review 3.  [Progress in oral antibiotic therapy in practice].

Authors:  H E Pichler
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Authors:  R R Muder; C Brennen; A M Goetz; M M Wagener; J D Rihs
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.

Authors:  F Soriano; R Fernández-Roblas; J Zapardiel; J L Rodríguez-Tudela; P Avilés; M Romero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

6.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

7.  Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Authors:  J M Diver; T Schollaardt; H R Rabin; C Thorson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 8.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 9.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.